VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE MKT: CVM) today announced that the University of Minnesota’s Masonic Cancer Center has becomes the 7th clinical site in the U.S. to join its Phase III head and neck cancer clinical trial of its investigational cancer immunotherapy treatment Multikine* (Leukocyte Interleukin, Injection).
CEL-SCI’s study is currently being conducted at about 60 active clinical centers on three continents and is expected to expand from 17 countries to a 20 countries with an estimated 880 patients to be enrolled by the end of 2015. According to the American Society of Clinical Oncology, head and neck cancers account for about 3% to 5% of all cancers in the United States.
Help employers find you! Check out all the jobs and post your resume.
